Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB (Sobi) is a leading biopharmaceutical company that specializes in developing and delivering innovative therapies for rare diseases. Focusing on hemophilia, inflammation, and genetic and metabolic diseases, Sobi is dedicated to improving the lives of patients worldwide. The company's portfolio includes a range of treatments, from plasma-derived and recombinant therapies to gene therapies and small molecules. Operating in over 30 countries, Sobi has a strong presence in Europe, North America, and the Middle East. With a team of experts and a passion for innovation, Sobi is at the forefront of the rare disease community, working tirelessly to bring hope and healing to patients and families affected by these challenging conditions.